MWNA
KDNY

Marshall Wace North America’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Marshall Wace North America’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,233
Closed -$568K – 1806
2021
Q2 		$568K Buy
+40,233
New +$644K ﹤0.01% 1141

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's KDNY Position: Q3 2021 in Review

Marshall Wace North America sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2021, closing a stake of 40,233 shares — an estimated $568K sold.

Marshall Wace North America first reported a position in KDNY in Q2 2021 and held it in 1 quarter. The position peaked at $568K in Q2 2021. 85 funds tracked by Wall St. Rank hold KDNY as of Q3 2021.

  • Marshall Wace North America reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 40,233 Chinook Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $568K.
  • Marshall Wace North America first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Chinook Therapeutics, Inc. Common Stock position peaked at $568K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.